Tag: intervene
InterVene receives US FDA 510(k) clearance for Recana thrombectomy system
InterVene recently announced it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Recana thrombectomy catheter system, which is...
First patient treated with InterVene’s Recana thrombectomy catheter system
InterVene announced today that the first patient has been treated with its Recana thrombectomy catheter system for venous in-stent restenosis (ISR).
The company shares...
InterVene announces US$13 million Series A financing to advance Recana system...
InterVene recently announced the closing of its US$13 million Series A financing round. The financing was co-led by new investor Treo Ventures and existing...
Deep venous valve technologies set to address “large unmet need worldwide”
The pursuit of a cure for deep venous valvular reflux—long considered to be the “holy grail” of deep venous disease—is underway, with new technologies...
Venous valve technologies set to address “large unmet need worldwide”
“I see a future where this technology may be used to treat people early and avoid the devastating long term consequences of venous insufficiency”...
InterVene’s BlueLeaf endovenous valve formation system granted FDA Breakthrough Device designation
InterVene recently announced that it has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for the company’s BlueLeaf endovenous valve...
TCT 2019: System for managing deep vein reflux wins Shark Tank...
At the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA), InterVene won the TCT-Shark Tank Innovation Competition for its novel endovenous system (BlueLeaf) for...
InterVene Raises $15 Million in Series B funding for catheter-based deep...
InterVene has announced it has raised US$15 million in a Series B financing round. The company’s BlueLeaf Endovenous Valve Formation System is the first catheter-based solution...